Authors
Mengfei Xu, Mariano A Molina, Cristina Gómez-Martín, Maaike M H S Dekker, Saba Ghasemi, Johan de Rooij, D Michiel Pegtel, Nienke E van Trommel, Renske D M Steenbergen
Published in
Translational oncology. Volume 71. Pages 102857. Epub Jun 16, 2026.
Abstract
Cervical cancer is primarily caused by persistent infection with high-risk human papillomavirus (hrHPV), which alters host RNA expression, including regulatory microRNAs (miRNAs). Because urine is emerging as a convenient biosource for cancer detection, we evaluated the feasibility of urinary miRNAs as non-invasive biomarkers for cervical cancer. We optimized miRNA isolation from whole urine and urine fractions using commercial RNA extraction kits, spike-in controls, and digital nanoplate PCR. Following identification of optimal conditions, IsoSeek small RNA sequencing was performed to profile miRNA expression in urine from women with cervical cancer (n = 20) and age-matched controls (n = 20). Differentially expressed candidates were then analytically confirmed by RT-qPCR. The Norgen RNA isolation kit applied to whole urine provided the most robust miRNA recovery. Sequencing identified significantly altered urinary levels of hsa-miR-143-3p and hsa-miR-204-3p in cervical cancer. The ratio of these miRNAs showed strong discriminatory performance for detecting cervical cancer using IsoSeek (AUC = 0.93) and remained robust after RT-qPCR analysis in the same cohort (AUC = 0.84). These findings support the feasibility of using urinary miRNA profiling for non-invasive biomarker discovery and highlight the hsa-miR-143-3p/hsa-miR-204-3p ratio as a promising candidate marker for cervical cancer detection.
PMID:
42302479
Bibliographic data and abstract were imported from PubMed on 14 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 4
- Comments 0